HER2 heterogeneity has been associated with shorter disease‐free survival and PFS and reduced pathologic CR rates in patients with HER2‐positive breast cancer after HER2‐targeted treatment.30, 33, 35, 36, 37. This evidence concerns the gene ERBB2 and breast carcinoma.